The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Open accessAbstract
The greatest unmet therapeutic need in Parkinson's disease is the development of treatment that slows the relentless progression of the neurodegenerative process. The concept of “disease modification” encompasses intervention types ranging from those designed to slow the underlying degeneration to treatments directed at regenerating or replacing lost neurons. To date all attempts to develop effective disease‐modifying therapy have failed. Many reasons have been proposed for these failures including our rudimentary understanding of disease pathogenesis and the assumption that each targeted mechanisms of disease apply to most patients with the same clinical diagnosis. Here we review all aspects of this broad field including general concepts and past challenges followed by a discussion of treatment approaches under the following 4 categories: (1) α‐synuclein, (2) pathogenic mechanisms distinct from α‐synuclein (most also potentially triggered by α‐synuclein toxicity), (3) non‐SNCA genetic subtypes of “PD,” and (4) possible disease‐modifying interventions not directly influencing the underlying PD pathobiology. We emphasize treatments that are currently under active clinical development and highlight a wide range of important outstanding questions and concerns that will need to be considered to advance the field of disease modification in PD. Critically, it is unknown whether the dysfunctional molecular pathways/organelles amenable to modification occur in a sequential fashion across most clinically affected individuals or manifest differentially in independent molecular subtypes of PD. It is possible that there is no “order of disruption” applicable to most patients but, rather, “type of disruption” applicable to subtypes dependent on unknown factors, including genetic variability and other causes for heterogeneity in PD. Knowing when (early vs late), which (eg, synaptic transmission, endosomal sorting and maturation, lysosomal degradation, mitochondrial biogenesis), and in whom (PD subtype) specific disrupted cell pathways are truly pathogenic versus compensatory or even protective, will be important in considering the use of single or combined (“cocktails”) putative disease‐modifying therapies to selectively target these processes. Beyond the current phase 2 or 3 studies underway evaluating treatments directed at oxidative stress (inosine), cytosolic Ca 2+ (isradipine), iron (deferiprone), and extracellular α‐synuclein (passive immunization), and upcoming trials of interventions affecting c‐Abl, glucagon‐like peptide‐1, and glucocerebrosidase, it might be argued that further trials in populations not enriched for the targeted pathogenic process are doomed to repeat the failures of the past. © 2018 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Self-citationPoewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationNgandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationLi, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,309
Self-citationDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Self-citationα-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
Self-citationAndrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., Bories, L., Cufi, M.-N., Dantoine, T., Dartigues, J.-F., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30040-6 · Cited by 838
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5593 · Cited by 619
van Charante, E. P. M., Richard, E., Eurelings, L. S., van Dalen, J.-W., Ligthart, S. A., van Bussel, E. F., Hoevenaar-Blom, M. P., Vermeulen, M., & van Gool, W. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30950-3 · Cited by 611
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588
Irwin, D. J., Grossman, M., Weintraub, D., Hurtig, H. I., Duda, J. E., Xie, S. X., Lee, E. B., Van Deerlin, V. M., Lopez, O. L., Kofler, J. K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30291-5 · Cited by 588
Long-term effects of exercise and physical therapy in people with Parkinson disease
Mak, M. K., Wong-Yu, I. S., Shen, X., & Chung, C. L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.128 · Cited by 549
Physiology and Anatomy of Possible Oscillators in the Central Nervous System
Rothwell, J. C. (2008) · Movement Disorders · doi:10.1002/mds.870131304 · Cited by 511
Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study
Adler, C. H., Beach, T. G., Hentz, J. G., Shill, H. A., Caviness, J. N., Driver-Dunckley, E., Sabbagh, M. N., Sue, L. I., Jacobson, S. A., Belden, C. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000641 · Cited by 503
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 450
A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies
Nalls, M. A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I. G., Chinnery, P. F., Morris, C. M., Theuns, J., Crosiers, D., Cras, P., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1925 · Cited by 439
Living on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 424
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
Mittal, S., Bjørnevik, K., Im, D. S., Flierl, A., Dong, X., Locascio, J. J., Abo, K. M., Long, E., Jin, M., Xu, B., et al. (2017) · Science · doi:10.1126/science.aaf3934 · Cited by 416
Paumier, K. L., Luk, K. C., Manfredsson, F. P., Kanaan, N. M., Lipton, J. W., Collier, T. J., Steece-Collier, K., Kemp, C. J., Celano, S., Schulz, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.003 · Cited by 392
Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease
Kalia, L. V., Lang, A. E., Hazrati, L.-N., Fujioka, S., Wszolek, Z. K., Dickson, D. W., Ross, O. A., Van Deerlin, V. M., Trojanowski, J. Q., Hurtig, H. I., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2704 · Cited by 384
Self-citationAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Use of ibuprofen and risk of Parkinson disease
Gao, X., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2011) · Neurology · doi:10.1212/wnl.0b013e31820f2d79 · Cited by 321
McNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J. M., Abramov, A. Y., Gegg, M., et al. (2014) · Brain · doi:10.1093/brain/awu020 · Cited by 321
Cell-based therapies for Parkinson disease—past insights and future potential
Barker, R. A., Drouin-Ouellet, J., & Parmar, M. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.123 · Cited by 306
Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease: Two Case Reports
Kefalopoulou, Z., Politis, M., Piccini, P., Mencacci, N., Bhatia, K., Jahanshahi, M., Widner, H., Rehncrona, S., Brundin, P., Björklund, A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4749 · Cited by 300
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 298
A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity
Perni, M., Galvagnion, C., Maltsev, A., Meisl, G., Müller, M. B. D., Challa, P. K., Kirkegaard, J. B., Flagmeier, P., Cohen, S. I. A., Cascella, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610586114 · Cited by 298
Halliday, M., Radford, H., Zents, K. A. M., Molloy, C., Moreno, J. A., Verity, N. C., Smith, E., Ortori, C. A., Barrett, D. A., Bushell, M., et al. (2017) · Brain · doi:10.1093/brain/awx074 · Cited by 293
Loria, F., Vargas, J. Y., Bousset, L., Syan, S., Salles, A., Melki, R., & Zurzolo, C. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1746-2 · Cited by 289
Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287
Self-citationSelegiline slows the progression of the symptoms of Parkinson disease
Pålhagen, S., Heinonen, E., Hägglund, J., Kaugesaar, T., Mäki-Ikola, O., Palm, R., & the Swedish Parkinson Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000204007.46190.54 · Cited by 271
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology
Wszolek, Z. K., Pfeiffer, R. F., Tsuboi, Y., Uitti, R. J., McComb, R. D., Stoessl, A. J., Strongosky, A. J., Zimprich, A., Müller-Myhsok, B., Farrer, M. J., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000125015.06989.db · Cited by 266
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
Karuppagounder, S. S., Brahmachari, S., Lee, Y., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2014) · Scientific Reports · doi:10.1038/srep04874 · Cited by 264 · cited 1×
“It has been shown to inhibit c-Abl and potentially protect against neuronal death in PD by reducing pathologic phosphorylation of both parkin and a-synuclein.(58,59) Unfortunately, the quality of the reported trial was poor, and there is the strong possibly that a placebo effect accounted for most if not all of the cl…”
BackgroundAutophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies
Xilouri, M., Brekk, O. R., & Stefanis, L. (2016) · Movement Disorders · doi:10.1002/mds.26477 · Cited by 261
Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10191 · Cited by 258
Self-citationBlesa, J., Trigo-Damas, I., Dileone, M., del Rey, N. L.-G., Hernandez, L. F., & Obeso, J. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.002 · Cited by 256
Parkinson's disease subtypes: lost in translation?
Marras, C., & Lang, A. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303455 · Cited by 253
Self-citationFirst‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers
Schenk, D. B., Koller, M., Ness, D. K., Griffith, S. G., Grundman, M., Zago, W., Soto, J., Atiee, G., Ostrowitzki, S., & Kinney, G. G. (2017) · Movement Disorders · doi:10.1002/mds.26878 · Cited by 252
Disease‐modifying strategies for Parkinson's disease
Kalia, L. V., Kalia, S. K., & Lang, A. E. (2015) · Movement Disorders · doi:10.1002/mds.26354 · Cited by 251
Self-citationThe Relationship of Parkinson Disease With Aging
Levy, G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1242 · Cited by 251
Complex I, iron, and ferritin in Parkinson's disease substantia nigra
Mann, V. M., Cooper, J. M., Daniel, S. E., Srai, K., Jenner, P., Marsden, C. D., & Schapira, A. H. V. (1994) · Annals of Neurology · doi:10.1002/ana.410360612 · Cited by 251
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Therapeutic approaches to target alpha-synuclein pathology
Brundin, P., Dave, K. D., & Kordower, J. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.003 · Cited by 242
Wallace, B. A., Ashkan, K., Heise, C. E., Foote, K. D., Torres, N., Mitrofanis, J., & Benabid, A.-L. (2007) · Brain · doi:10.1093/brain/awm137 · Cited by 235
Mandler, M., Valera, E., Rockenstein, E., Weninger, H., Patrick, C., Adame, A., Santic, R., Meindl, S., Vigl, B., Smrzka, O., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1256-4 · Cited by 229
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
Jucaite, A., Svenningsson, P., Rinne, J. O., Cselényi, Z., Varnäs, K., Johnström, P., Amini, N., Kirjavainen, A., Helin, S., Minkwitz, M., et al. (2015) · Brain · doi:10.1093/brain/awv184 · Cited by 222
Mahul-Mellier, A.-L., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., Lamontanara, A. J., Bisquertt, A., Eliezer, D., Masliah, E., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt674 · Cited by 219
Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration
Mor, D. E., Tsika, E., Mazzulli, J. R., Gould, N. S., Kim, H., Daniels, M. J., Doshi, S., Gupta, P., Grossman, J. L., Tan, V. X., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4641 · Cited by 217
Zhao, H. T., John, N., Delic, V., Ikeda-Lee, K., Kim, A., Weihofen, A., Swayze, E. E., Kordasiewicz, H. B., West, A. B., & Volpicelli-Daley, L. A. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.08.002 · Cited by 212
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616152114 · Cited by 203
Ritchie, C. W., Molinuevo, J. L., Truyen, L., Satlin, A., Van der Geyten, S., & Lovestone, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00454-x · Cited by 202
Rizzone, M. G., Fasano, A., Daniele, A., Zibetti, M., Merola, A., Rizzi, L., Piano, C., Piccininni, C., Romito, L. M., Lopiano, L., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.01.012 · Cited by 193
Science, medicine, and the future: Parkinson's disease
Schapira, A. H. V. (1999) · BMJ · doi:10.1136/bmj.318.7179.311 · Cited by 187
Precision medicine for disease modification in Parkinson disease
Espay, A. J., Brundin, P., & Lang, A. E. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.196 · Cited by 180
Self-citationEspay, A. J., Schwarzschild, M. A., Tanner, C. M., Fernandez, H. H., Simon, D. K., Leverenz, J. B., Merola, A., Chen‐Plotkin, A., Brundin, P., Kauffman, M. A., et al. (2017) · Movement Disorders · doi:10.1002/mds.26913 · Cited by 178
Self-citationStage‐dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease
Dijkstra, A. A., Voorn, P., Berendse, H. W., Groenewegen, H. J., Bank, N. B., Rozemuller, A. J. M., & van de Berg, W. D. J. (2014) · Movement Disorders · doi:10.1002/mds.25952 · Cited by 176
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
West, A. B. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.019 · Cited by 176
Coles, L. D., Tuite, P. J., Öz, G., Mishra, U. R., Kartha, R. V., Sullivan, K. M., Cloyd, J. C., & Terpstra, M. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1008 · Cited by 170
Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
AlDakheel, A., Kalia, L. V., & Lang, A. E. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0218-1 · Cited by 165
Self-citationConcomitant pathologies among a spectrum of parkinsonian disorders
Dugger, B. N., Adler, C. H., Shill, H. A., Caviness, J., Jacobson, S., Driver-Dunckley, E., & Beach, T. G. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.012 · Cited by 161
α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era
Visanji, N. P., Brotchie, J. M., Kalia, L. V., Koprich, J. B., Tandon, A., Watts, J. C., & Lang, A. E. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.09.003 · Cited by 161
Self-citationParkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
Ritz, B., Lee, P.-C., Lassen, C. F., & Arah, O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000879 · Cited by 160
Malek, N., Lawton, M. A., Swallow, D. M. A., Grosset, K. A., Marrinan, S. L., Bajaj, N., Barker, R. A., Burn, D. J., Hardy, J., Morris, H. R., et al. (2016) · Movement Disorders · doi:10.1002/mds.26698 · Cited by 158
Gendelman, H. E., Zhang, Y., Santamaria, P. M., Olson, K. E., Schutt, C. R., Bhatti, D., Shetty, B. L. D., Lu, Y., Estes, K. A., Standaert, D. G., et al. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0013-5 · Cited by 153
LRRK2 Pathways Leading to Neurodegeneration
Cookson, M. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0564-y · Cited by 145
Neuropathology of α‐synuclein propagation and braak hypothesis
McCann, H., Cartwright, H., & Halliday, G. M. (2015) · Movement Disorders · doi:10.1002/mds.26421 · Cited by 141
Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial
Postuma, R. B., Anang, J., Pelletier, A., Joseph, L., Moscovich, M., Grimes, D., Furtado, S., Munhoz, R. P., Appel-Cresswell, S., Moro, A., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004568 · Cited by 135
Self-citationTargeting urate to reduce oxidative stress in Parkinson disease
Crotty, G. F., Ascherio, A., & Schwarzschild, M. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.06.017 · Cited by 135
Xu, Y., Zhang, Y., Quan, Z., Wong, W., Guo, J., Zhang, R., Yang, Q., Dai, R., McGeer, P. L., & Qing, H. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1995-9 · Cited by 134
The progression of Parkinson disease: A hypothesis
Lang, A. E. (2007) · Neurology · doi:10.1212/01.wnl.0000257110.91041.5d · Cited by 117
Self-citationSynuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
Maguire‐Zeiss, K. A., Short, D. W., & Federoff, H. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.014 · Cited by 115
Potential Modes of Intercellular α-Synuclein Transmission
Valdinocci, D., Radford, R. A. W., Siow, S. M., Chung, R. S., & Pountney, D. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020469 · Cited by 115
Ritchie, K. A., Ropacki, M. T., Albala, B., Harrison, J., Kaye, J. A., Kramer, J. H., RANDOLPH, C. C., & Ritchie, C. W. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.07.154 · Cited by 112
Musacchio, T., Rebenstorff, M., Fluri, F., Brotchie, J. M., Volkmann, J., Koprich, J. B., & Ip, C. W. (2017) · Annals of Neurology · doi:10.1002/ana.24947 · Cited by 108
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
Grolez, G., Moreau, C., Sablonnière, B., Garçon, G., Devedjian, J.-C., Meguig, S., Gelé, P., Delmaire, C., Bordet, R., Defebvre, L., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0331-3 · Cited by 103
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model
Kohl, Z., Winner, B., Ubhi, K., Rockenstein, E., Mante, M., Münch, M., Barlow, C., Carter, T., Masliah, E., & Winkler, J. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07933.x · Cited by 101
Strategies for bringing stem cell-derived dopamine neurons to the clinic
Kirkeby, A., Parmar, M., & Barker, R. A. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.11.011 · Cited by 94
Kordower, J. H., Goetz, C. G., Chu, Y., Halliday, G. M., Nicholson, D. A., Musial, T. F., Marmion, D. J., Stoessl, A. J., Sossi, V., Freeman, T. B., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24820 · Cited by 93
Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database
Liu, G., Sterling, N. W., Kong, L., Lewis, M. M., Mailman, R. B., Chen, H., LESLIE, D. L., & Huang, X. (2017) · Movement Disorders · doi:10.1002/mds.27006 · Cited by 93
Oxidative stress in Parkinson's disease
Schapira, A. H. V. (1995) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1995.tb01022.x · Cited by 91
Development of P assive I mmunotherapies for S ynucleinopathies
Bergström, A., Kallunki, P., & Fog, K. (2015) · Movement Disorders · doi:10.1002/mds.26481 · Cited by 91
Ubhi, K. K., Inglis, C. A., Mante, M., Patrick, C., Adame, A., Spencer, B. J., Rockenstein, E. M., May, V. E. L., Winkler, J., & Masliah, E. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.008 · Cited by 88
Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment
Siderowf, A. D., & Stern, M. B. (2009) · Annals of Neurology · doi:10.1002/ana.21462 · Cited by 87
Active immunization therapies for Parkinson's disease and multiple system atrophy
Schneeberger, A., Tierney, L., & Mandler, M. (2015) · Movement Disorders · doi:10.1002/mds.26377 · Cited by 87
Dopaminergic transplantation for parkinson's disease: Current status and future prospects
Olanow, C. W., Kordower, J. H., Lang, A. E., & Obeso, J. A. (2009) · Annals of Neurology · doi:10.1002/ana.21778 · Cited by 81
Self-citationChallenges in detecting disease modification in Parkinson's disease clinical trials
Athauda, D. S., & Foltynie, T. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.07.019 · Cited by 75
A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)
Biglan, K., Oakes, D., Lang, A. E., Hauser, R. A., Hodgeman, K., Greco, B., Lowell, J., Rockhill, R. L., Shoulson, I., Venuto, C. S., et al. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.412 · Cited by 73
Self-citationInsights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease
Volta, M., Milnerwood, A. J., & Farrer, M. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00186-6 · Cited by 71
Trial designs used to study neuroprotective therapy in Parkinson's disease
Lang, A. E., Melamed, E., Poewe, W. H., & Rascol, O. (2012) · Movement Disorders · doi:10.1002/mds.24997 · Cited by 71
Self-citationTrophic factors for Parkinson's disease: To live or let die
Olanow, C. W., Bartus, R. T., Volpicelli‐Daley, L. A., & Kordower, J. H. (2015) · Movement Disorders · doi:10.1002/mds.26426 · Cited by 69
S tudy of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration
Sánchez-Contreras, M., Heckman, M. G., Tacik, P. M., Diehl, N. N., Brown, P. H., Soto‐Ortolaza, A. I., Christopher, E. A., Walton, R. L., Ross, O. A., Golbe, L. I., et al. (2016) · Movement Disorders · doi:10.1002/mds.26815 · Cited by 67
Combination therapies: The next logical Step for the treatment of synucleinopathies?
Valera, E., & Masliah, E. (2015) · Movement Disorders · doi:10.1002/mds.26428 · Cited by 64
Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
Kienzl, E., Jellinger, K. A., Stachelberger, H., & Linert, W. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00458-0 · Cited by 62
McGhee, D. J. M., Ritchie, C. W., Zajicek, J., & Counsell, C. E. (2016) · BMC Neurology · doi:10.1186/s12883-016-0606-3 · Cited by 62
Kahn, E. N., D’Haese, P.-F., Dawant, B. M., Allen, L. A., Kao, C., Charles, D. P., & Konrad, P. E. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300008 · Cited by 61
Fischer, D. L., Kemp, C. J., Cole-Strauss, A., Polinski, N. K., Paumier, K. L., Lipton, J. W., Steece‐Collier, K., Collier, T. J., Buhlinger, D. J., & Sortwell, C. E. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2060-16.2017 · Cited by 54
Building a roadmap for developing combination therapies for Alzheimer’s disease
Perry, D. P., Sperling, R. A., Katz, R. G., Berry, D. A., Dilts, D. M., Hanna, D. L., Salloway, S., Trojanowski, J. Q., Bountra, C., Krams, M., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.996551 · Cited by 53
Targeting LRRK2 in Parkinson’s disease: an update on recent developments
Chan, S. L., & Tan, E. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1323881 · Cited by 51
Statin therapy prevents the onset of Parkinson disease in patients with diabetes
Lin, K., Yang, C., Lee, M., Ho, S., Liu, C., & Shin, S. (2016) · Annals of Neurology · doi:10.1002/ana.24751 · Cited by 48
Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease
Paumier, K. L., Siderowf, A. D., Auinger, P., Oakes, D., Madhavan, L., Espay, A. J., Revilla, F. J., Collier, T. J., & for the Parkinson Study Group Genetics Epidemiology Working Group (2012) · Movement Disorders · doi:10.1002/mds.24978 · Cited by 47
Self-citationZeroing in on neurodegenerative α-synuclein
Kingwell, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.95 · Cited by 47
Hacker, M. L., Tonascia, J., Turchan, M., Currie, A. D., Heusinkveld, L. E., Konrad, P. E., Davis, T. L., Neimat, J. S., Phibbs, F. T., Hedera, P., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.08.008 · Cited by 46
Clinical approaches to the development of a neuroprotective therapy for PD
Olanow, C. W., Kieburtz, K. D., & Katz, R. G. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.06.018 · Cited by 38
Charting a path toward combination therapy for Alzheimer’s disease
Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995168 · Cited by 37
Targeting α‐Synuclein as a therapy for Parkinson's disease: The battle begins
Olanow, C. W., & Kordower, J. H. (2017) · Movement Disorders · doi:10.1002/mds.26935 · Cited by 30
Swallow, D. M. A., Lawton, M., Grosset, K. A., Malek, N., Klein, J. C., Baig, F., Ruffmann, C., Bajaj, N. P. S., Barker, R. A., Ben‐Shlomo, Y., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313642 · Cited by 29
Paumier, K. L., Sortwell, C. E., Madhavan, L., Terpstra, B. T., Daley, B. F., & Collier, T. J. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.02.005 · Cited by 27
Can lifestyle changes prevent cognitive impairment?
Kivipelto, M., Mangialasche, F., & Ngandu, T. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30080-7 · Cited by 27
Statin adherence and the risk of Parkinson's disease: A population-based cohort study
Rozani, V., Giladi, N., El‐Ad, B., Gurevich, T., Tsamir, J., Hemo, B., & Peretz, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175054 · Cited by 24
Embryonic development of selectively vulnerable neurons in Parkinson’s disease
Oliveira, M. A. P., Balling, R., Smidt, M. P., & Fleming, R. M. T. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0022-4 · Cited by 24
Synuclein and dopamine: the Bonnie and Clyde of Parkinson's disease
Roy, S. (2017) · Nature Neuroscience · doi:10.1038/nn.4660 · Cited by 22
Rowland, N. C., Kalia, S. K., Kalia, L. V., Larson, P., Lim, D. A., & Bankiewicz, K. S. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.51 · Cited by 20
Verschuur, C. V. M., Suwijn, S. R., Post, B., Dijkgraaf, M. G. W., Bloem, B. R., van Hilten, J. J., van Laar, T., Tissingh, G., Deuschl, G., Lang, A. E., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0491-1 · Cited by 19
Self-citationDoes smoking impact dopamine neuronal loss in de novo Parkinson disease?
Lee, Y., Oh, J. S., Chung, S. J., Chung, S. J., Kim, S., Nam, C. M., Lee, P. H., Kim, J. S., & Sohn, Y. H. (2017) · Annals of Neurology · doi:10.1002/ana.25082 · Cited by 18
New perspectives on study designs for evaluating neuroprotection in Parkinson's disease
Thibault, L., Rascol, O., Corvol, J., Ferreira, J. P., Defebvre, L., Deplanque, D., Bordet, R., Moreau, C., & Devos, D. (2017) · Movement Disorders · doi:10.1002/mds.27055 · Cited by 12
Cited by
LRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
Trial of Prasinezumab in Early-Stage Parkinson’s Disease
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202867 · Cited by 421
New insights into the complex role of mitochondria in Parkinson’s disease
Grünewald, A., Kumar, K. R., & Sue, C. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.09.003 · Cited by 364
Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis
Johnson, M. E., Stecher, B., Labrie, V., Brundin, L., & Brundin, P. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.09.007 · Cited by 310
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Metadata
- Authors
- Lang, A. E., & Espay, A. J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2018-04-11
- Volume
- 33
- Issue
- 5
- Pages
- 660-677
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2797709183
- Cited by
- 370
- References
- 134
- FWCI
- 26.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.